Latest Insider Transactions at Innoviva, Inc. (INVA)
This section provides a real-time view of insider transactions for Innoviva, Inc. (INVA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Innoviva, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Innoviva, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 25
2022
|
George Bickerstaff Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,647
+8.44%
|
-
|
|
Apr 25
2022
|
Deborah Birx Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,647
+22.94%
|
-
|
|
Mar 01
2022
|
Marianne Zhen Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,691
+14.69%
|
-
|
|
Feb 18
2022
|
Marianne Zhen Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,277
-6.61%
|
$43,263
$19.99 P/Share
|
|
Nov 19
2021
|
Marianne Zhen Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
758
-2.15%
|
$12,886
$17.05 P/Share
|
|
Aug 20
2021
|
Marianne Zhen Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
760
-2.15%
|
$11,400
$15.94 P/Share
|
|
Aug 20
2021
|
Marianne Zhen Chief Accounting Officer |
BUY
Open market or private sale
|
Direct |
1,129
+3.09%
|
$16,935
$15.89 P/Share
|
|
Aug 19
2021
|
Marianne Zhen Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,802
-7.13%
|
$44,832
$16.02 P/Share
|
|
May 24
2021
|
George Bickerstaff Director |
BUY
Open market or private purchase
|
Direct |
10,000
+7.43%
|
$130,000
$13.46 P/Share
|
|
May 21
2021
|
George Bickerstaff Director |
BUY
Open market or private purchase
|
Direct |
10,000
+8.03%
|
$120,000
$12.97 P/Share
|
|
May 20
2021
|
Marianne Zhen Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
759
-1.89%
|
$9,867
$13.32 P/Share
|
|
May 20
2021
|
Glaxosmithkline PLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
32,005,260
-100.0%
|
$384,063,120
$12.25 P/Share
|
|
May 14
2021
|
Deborah Birx Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,482
+36.94%
|
-
|
|
May 14
2021
|
Sarah J. Schlesinger Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,482
+18.79%
|
-
|
|
May 14
2021
|
Mark Di Paolo Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,482
+18.79%
|
-
|
|
May 14
2021
|
Kostas D Odysseas Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,482
+18.01%
|
-
|
|
May 14
2021
|
George Bickerstaff Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,482
+14.32%
|
-
|
|
May 14
2021
|
Jules Haimovitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,482
+16.61%
|
-
|
|
Mar 29
2021
|
Deborah Birx Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,612
+11.54%
|
-
|
|
Mar 29
2021
|
Marianne Zhen Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,305
+21.16%
|
-
|
|
Feb 19
2021
|
Marianne Zhen Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,108
-6.98%
|
$23,188
$11.74 P/Share
|
|
Nov 20
2020
|
Marianne Zhen Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
798
-2.57%
|
$7,980
$10.95 P/Share
|